SOUTH SAN FRANCISCO, CA, Centivax, a biotechnology company engineering vaccines and therapies, announced a $45 million Series A.
Centivax, a biotechnology company engineering vaccines and therapies, announced a $45 million Series A led by Future Ventures, with participation from NFX, BOLD Capital Partners, Base4 Capital, Kendall Capital Partners, and Amplify Partners.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
